Repligen
Repligen Corp is an American bioprocessing technology provider manufacturing specialized equipment and consumables for biological drug manufacturing. The company produces protein A affinity ligands, cell retention systems, chromatography columns, filtration systems, and fluid management products under brands like XCell and KrosFlo. Revenue is principally derived from direct product sales of bioprocessing hardware and single-use consumables to biopharmaceutical companies and contract manufacturers. Core end markets encompass biotechnology firms, global pharmaceutical corporations, and contract development manufacturing organizations worldwide. Repligen holds a market-leading position in bioprocessing filtration, chromatography, and cell retention tools supporting biologic drug production. The corporation is headquartered in Waltham, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
16 of the funds FundTelligence covers report a position in Repligen.
- Legal name
- Repligen Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 16
Funds holding Repligen
- Schroder ISF US Smaller Companies Impact — Schroders · 2.98 % (full portfolio disclosed, June 2026)
- Lannebo Global Growth — Lannebo · 1.61 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 1.49 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Equity Impact — Schroders · 1.32 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Smaller Companies — Schroders · 1.08 % (full portfolio disclosed, June 2026)
- BNP US Growth — BNP Paribas · 0.98 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.89 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.73 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 16 funds holding it.